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Abstract
Background: The aim of this study was to develop a standardized method to reconstruct persons’ individual viral
load (VL) courses to determine viral suppression and duration of viremia for the HIV care continuum in Germany
using longitudinal cohort data.
Methods: We analyzed data from two large, multi-center German cohort studies under the direction of the Robert
Koch Institute. We included data from 1999 to 2018 of all diagnosed people and of people who initiated
antiretroviral treatment (ART). We developed a model generating virtual VL values and an individual VL course
corresponding to real VL measurements with a maximum distance of 180 days, considering ART status and VL
dynamics. If the distance between VL measurements was > 180 days, the time between was defined as gap time.
Additionally, we considered blips, which we defined as a single detectable VL < 1000 copies/ml within 180 days.
Results: A total of 22,120 people (164,691 person-years, PY) after ART initiation were included in the analyses. The
proportion of people with viral suppression (VL < 50 copies/ml) increased from 34% in 1999 to 93% in 2018. The
proportion of people with VL < 200 copies/ml increased from 47% in 1999 to 96% in 2018. The proportion of
people with viremia > 1000 copies/ml decreased from 37% in 1999 to 3% in 2018. The proportion of people with
gap time fluctuated and ranged between 18 and 28%. An analysis of the first VL after gap time showed that 90%
showed viral suppression, 5% VL between 50- < 1000 copies/ml and 5% VL > 1000 copies/ml.
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: SchmidtD@rki.de
1Department of Infectious Disease Epidemiology, Robert Koch Institute,
Berlin, Germany
2Institute of Public Health, Charité – Universitätsmedizin Berlin, Berlin,
Germany
Full list of author information is available at the end of the article
Schmidt et al. BMC Public Health          (2021) 21:200 
https://doi.org/10.1186/s12889-020-10088-7
(Continued from previous page)
Conclusion: We provide a method for estimating viral suppression and duration of viremia using longitudinal VL data.
We observed a continuous and remarkable increase of viral suppression. Furthermore, a notable proportion of those
with viremia showed low-level viremia and were therefore unlikely to transmit HIV. Individual health risks and HIV drug
resistance among those with low-level viremia are problematic, and viral suppression remains the goal. In 2018, 93 and
96% of people after ART initiation showed VL < 50 copies/ml and VL < 200 copies/ml, respectively. Therefore, using the
threshold of VL < 200 copies/ml, Germany reached the UNAIDS 95 target of viral suppression since 2017.
Keywords: Viral suppression, HIV care continuum, Treatment success, HIV cascade
Background
The Joint United Nations Programme on HIV/AIDS
(UNAIDS) targets to accelerate the fight against HIV
and to end the AIDS epidemic by 2030 aim to increase
the proportion of people living with HIV (PLHIV) know-
ing their diagnosis, of people with diagnosed HIV infec-
tion receiving antiretroviral treatment (ART) and of
people receiving ART being virally suppressed to 90% by
2020 and to 95% by 2030 [1–3].
It is estimated that, in 2018, 37.9 million people were
living with HIV worldwide, and 23.3 million people were
accessing ART. Globally, in 2018, 79% of PLHIV knew
their status. Among people who knew their HIV status,
78% were accessing treatment. Among those people,
86% were virally suppressed. This statistic is a consider-
able increase in recent years compared to 2010, when
only 24% of all people living with HIV were accessing
treatment. New HIV infections have declined by ap-
proximately 16% since 2010 to 1.7 million new infections
in 2018. Since 2010, the number of people who have
died from AIDS-related illnesses worldwide has
decreased by 33% to 770,000 in 2018 [4]. However, there
are large differences across regions and countries regard-
ing the HIV care continuum, with less than 50% of all
people living with HIV accessing ART in Eastern
Europe, central Asia, the Middle East and North Africa,
and new HIV infections and AIDS-related deaths are
rising in these regions [4, 5]. Additionally, for the first
time since 2000, less funding was available for AIDS
response in low- and middle-income countries -- almost
US$ 1 billion less than in 2017 [4]. In addition, chal-
lenges with data quality, appropriate data sources and
the absence of standardized definitions could hamper
comparisons across countries [6].
In Germany, an increasing number of PLHIV are re-
ceiving ART [7, 8], and it is estimated that, at the end of
2018, of all PLHIV in Germany, 88% were diagnosed,
and 93% of diagnosed were under ART [8]. The Robert
Koch Institute (RKI) reports numbers for the German
HIV care continuum to national and international stake-
holders using the different available data sources. How-
ever, there is no national database containing follow-up
clinical or treatment data on PLHIV. HIV surveillance,
in addition to reports on diagnosed HIV/AIDS cases, re-
quires additional surveillance tools, which are imple-
mented with longitudinal clinical cohort studies at the
RKI [9, 10]. In a former study, the RKI working group
developed a method to determine the number of PLHIV
receiving ART in Germany using ART prescription data
and national clinical cohort data from the Clinical
Surveillance of HIV Disease (ClinSurv HIV) [7]. This
method, which was selected for a compendium of good
HIV practices in the WHO European Region [11], has
been continuously used for the second stage of the
German HIV care continuum in the annual national
HIV estimates of the RKI [8]. However, consistent
methods for all stages of a standardized HIV continuum
of care for Germany, especially for the numbers and
proportions of people and their person-time with viral
suppression, have not yet been published.
The main goal of ART is sustained viral suppression,
which subsequently leads to several benefits. These
benefits include immune recovery and decreased im-
mune activation [12], prevention of HIV-related mor-
bidity and mortality [13–15], reduction in non-AIDS
diseases, such as cancer or cardiovascular disease [16],
prevention of HIV transmission [17, 18] and avoiding
the development of HIV drug resistance [19]. In
Germany, effective ART evidenced by viral suppression
is required by reimbursement regulations for health
insurance. Hence, it is usually monitored every three
months by viral load (VL) testing. Longer periods
without VL controls are critical because, in cases of
viral failure, immediate action would be required to
avoid evolution of viral resistance or clinical progres-
sion of HIV disease.
Viral suppression is commonly defined as a VL test
result below the detection limit or a certain threshold
at the most recent VL test in one year [20–22]. How-
ever, such an approach does not address the dynamics
of VL progression over time and could lead to biased
results when the last VL is not representative of the
respective year. We therefore aimed to present an
alternative approach using longitudinal data, including
all available VL measurements and persons’ individual
ART histories.
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With this study, we aimed to:
a) develop a model to determine the durations and
proportions of viral suppression and viremia
among PLHIV to be used for the HIV care
continuum;
b) determine the numbers and proportions of PLHIV
and of person-time with viral suppression and
viremia between 1999 and 2018 using national
clinical cohort data;
c) compare the results of the conventional method
with those of our longitudinal model; and
d) evaluate the UNAIDS target of viral suppression for
PLHIV in Germany.
Methods
HIV surveillance in Germany
National HIV/AIDS surveillance in Germany is regulated
by the national Protection Against Infection Act and is
based on mandatory reports of newly diagnosed cases of
HIV infection and voluntary reporting of AIDS cases to
the RKI, which is the federal institute of public health
under the umbrella of the German Ministry of Health
[23]. In addition, continuous monitoring of the course of
HIV infection, including HIV treatment, is performed in
HIV cohort studies at the RKI.
Study population and data
We analyzed data from two large German cohort studies,
the Clinical Surveillance of HIV Disease (ClinSurv HIV)
and the HIV-1 Seroconverter cohort; both studies are
under the direction of the RKI. For this analysis, cohort
data between 1999 and 2018 of people with at least two
VL measurements were included.
The ClinSurv HIV cohort is the base for a nationwide,
prospective, multi-center, open, long-term observational
cohort study for the clinical surveillance of HIV in
Germany. Data on demographics, detailed information
on the initiation, composition and discontinuation of in-
dividuals’ daily ART, laboratory parameters and clinical
events are collected biannually in a standardized format.
ClinSurv HIV is the largest available nationwide source
of PLHIV in Germany. The study design is described in
detail elsewhere [9].
The HIV-1 Seroconverter cohort is the basis for a
nationwide, multi-center, open, long-term observational
cohort study of HIV-1-positive people with a known or
reliably estimated date of HIV-1 seroconversion. Socio-
demographic and clinical data from each participant
were collected at the time of enrollment and at yearly
follow-ups. Detailed descriptions of the study methods
can be found elsewhere [10, 24, 25].
Developing a model and method to determine viral
suppression and viremia
We developed a model to reconstruct the individual VL
course of people to estimate the duration and proportion
of viral suppression and viremia using longitudinal data,
including all available VL measurements, taking into
account ART status and VL dynamics. In this model, we
looked for real VL measurements with a maximum dis-
tance of 180 days. We then connected the measurements
linearly and generated virtual VL values for every 10-day
interval along the line. The 10-day interval was chosen
because it offers sufficient accuracy with manageable
data volumes. Additionally, we took into account the
ART status of the people when we connected the real
VL measurements. For example, if a person was coming
from an ART naïve time into therapy, we did not con-
nect the VL measurements linearly, assuming that the
VL decrease started with ART initiation; therefore, a
virtual VL value was generated according to the ART
status, and a horizontal line was drawn from the higher
VL measurement to the ART start, and then the line
decreased to the lower VL measurement. Similarly, if a
person’s viral load increased and an interruption were
documented in the ART history, we assumed that the
increase did not necessarily occur from the previous VL
measurement but rather stemmed from the ART inter-
ruption (see Fig. 1). VL measurements without a con-
secutive VL measurement within 180 days were assigned
a lifetime of 30 days prior to and after the VL measure-
ment. The remaining time not covered by our model
was defined as a longer period without VL control or so-
called gap time. Additionally, we considered blips, which
we defined as a single detectable VL < 1000 copies/ml
within 180 days with a subsequent undetectable VL.
VL was a priori stratified into the following groups:
VL < 50 copies/ml, VL 50- < 200 copies/ml, VL 200- <
500 copies/ml, VL 500- < 1000 copies/ml, VL 1000- < 10,
000 copies/ml, VL 10,000- < 100,000 copies/ml, VL 100,
000- < 1000,000 copies/ml, and VL ≥1000,000 copies/ml.
We analyzed the proportion of person-time with
viral suppression and viremia over time in the total
study population, indicating that, at different points
in time, different people can have the same propor-
tion of person-time and viral suppression. We also re-
port the number and proportion of people with viral
suppression and viremia, the interquartile range (IQR)
and median person-time with viral suppression and
viremia, and the IQR and median proportion of viral
suppression and viremia to the observation time on
an individual level.
Furthermore, we analyzed the time with viral suppres-
sion and viremia on an individual level, such as the pro-
portion of people with continuous viral suppression over
a period of time.
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Viral suppression and viremia from 1999 to 2018
People observed between 1999 and 2018 with at least
two VLs were included. We determined viral suppres-
sion and viremia over time: (i) among all PLHIV in the
cohort studies regardless of their ART status, including
ART-naïve and treated person-time; and (ii) among
PLHIV after ART initiation regardless of whether they
were continuously under ART, including person-time
with documented interruptions or gaps in treatment.
Viral suppression was defined as VL < 50 copies/ml ac-
cording to the German-Austrian ART guidelines [26].
When evaluating the UNAIDS target of viral suppression
for PLHIV, we also report the proportion of person-time
with VL < 200 copies/ml for comparability. This thresh-
old of < 200 copies/ml for population-level monitoring is
consistent with the guidelines and recommendations of
several institutions, such as the US Centers for Disease
Control and Prevention and the European Centre for
Disease Prevention and Control [20, 27].
We determined viral suppression and viremia over
time among PLHIV after ART initiation with the con-
ventional method, using the most recent VL in each
year, and we compared the results with those of our lon-
gitudinal model.
To further investigate potential misclassification using
the conventional method with a single VL during one
year, we determined the number and proportion of
PLHIV with continuous viral suppression over a year-
long observation period on an individual level and com-
pared it with the results of the conventional method
using the most recent VL in one year.
The results on the proportion of people and person-
time with viral suppression and viremia in the respective
year are reported excluding gap time. The proportion of
people with gap time is reported separately. Further-
more, we performed separate sensitivity analyses in the
group of people with gap time to assess their VL status.
Analysis of people with longer periods without VL control
(gap time)
We report the proportion of person-time with gap time
on the total observation time in the study population,
the number and proportion of people with gap time, the
IQR and median gap time, and the IQR and median pro-
portion of gap time to the observation time on an indi-
vidual level.
In people with gap time, the last VL measurement be-
fore and the first VL measurement after having gap time
were analyzed to approximate the VL status of the
people during gap time. This approach is in accordance
with methods used in other studies [28, 29]. The last
and first VL before and after gap time were analyzed for
the recent study period from 2015 to 2018. We deter-
mined the overall proportion of people with viral sup-
pression at the last and first VL before and after gap
time. Furthermore, the congruence of the last and first
VL on an individual level was determined. For the ana-
lysis of the congruence between the last and first VL be-
fore and after gap time, the proportions of people with
viral suppression at both VL measurements, both VL
measurements 50- < 1000 copies/ml, both VL measure-
ments > 1000 copies/ml, the proportion of people with a
VL increase (last VL < first VL) and the proportion of
people with a VL decrease (last VL > first VL) were de-
termined. Among those with detectable VL, we also re-
port the IQR and median VL in each group.
To approximate the impact of gap time on the overall
viral suppression in people who initiated ART, we
Fig. 1 Model to determine viral suppression and viremia using longitudinal data on VL and ART history
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calculated the resulting proportion of viral suppression
after considering for viremic gap time. Therefore, we de-
termined the proportion of viremia at the first VL meas-
urement after gap time, determined the proportion of
gap time among all people who initiated ART, then de-
termined the resulting proportion of viremic gap
time and viral suppression among all people who initi-
ated ART.
Analysis of antiretroviral treatment regimens over time
The ART regimens were separated into mainly used reg-
imens according to the German-Austrian ART guide-
lines [26], consisting of nucleoside reverse transcriptase
inhibitors (NRTIs) with either a non-nucleoside reverse
transcriptase inhibitor (NNRTI), a protease inhibitor
(PI), or an integrase strand transfer inhibitor (INSTI).
Further ART was classified into triple-class regimens,
NRTI only, NRTI-sparing regimens, attachment inhibi-
tor (AI) containing, salvage regimens (3 drug classes and
AI or fusion inhibitor (FI) or 4 drug classes), study medi-
cation, ART interruption, not fully active ART and ART
gap.
We created our analytic sample in SQL Server Manage-
ment Studio software, version 17.4 (Microsoft Corpor-
ation Redmond, WA, USA), and conducted the statistical
analysis in Stata software, version 15.1 (StataCorp., College
Station, TX, USA). Figures were created using Microsoft
Excel and Microsoft Power Point 2019.
Results
Study population
A total of 24,569 people with at least two documented
VLs from the ClinSurv HIV and the HIV-1 Seroconver-
ter cohorts were enrolled and followed for a median of
5.9 years (IQR 2.4–11), totaling 171,990 person-years
(PY). The total number of real VL measurements was
570,753, the median number of VL measurements per
person was 18 (IQR 7–35), and VL monitoring occurred
at a median frequency of every 91 days (IQR 64–112).
With the model, 4,541,141 virtual VL values were gener-
ated. The real VL measurement and the virtual VL value
occurred on the same date in 69,297 cases.
The majority of people, 88.4% (N = 21,716), were en-
rolled in the ClinSurv HIV cohort, 9.2% (N = 2264) were
enrolled in the HIV-1 Seroconverter cohort, and 2.4%
(N = 589) were enrolled in both cohort studies. Of the
24,569 people, 22,120 initiated ART, and 2449 were
ART naïve at the end of observation. The characteristics
of the study population are summarized in Table 1.
On an individual level, a total of 88% (21,584/24,569)
achieved viral suppression at any time, and 12% (2985/
24,569) never achieved viral suppression. Of all subjects,
89% (21,967/24,569) showed viremia at any time, and
82% (20,249/24,569) showed viremia with VL > 1000
copies/ml. The total median observation time was 2180
days (interquartile range (IQR) 860–4020). The median
person-time with viral suppression among all people was
930 days (IQR 190–2140). The resulting individual pro-
portion of person-time with viral suppression to the ob-
servation time had a median of 52% (IQR: 18–77).
Excluding gap time, the proportion of person-time with
viral suppression to the observation time had a median
of 75% (IQR: 37–92). The median person-time with
viremia with VL > 1000 copies/ml was 120 days (IQR
40–420). The individual proportion of person-time with
viremia with VL ≥1000 copies/ml to the observation
time had a median of 8% (IQR: 1.8–24). Excluding gap
time, the proportion of viremia with VL ≥1000 copies/
ml to the observation time had a median of 12% (IQR:
2.3–40).
Viral suppression and viremia from 1999 to 2018
Among all diagnosed PLHIV
Based on the longitudinal model, the proportion of
person-time with viral suppression (VL < 50 copies/ml)
of the 24,569 people increased over time from 22.2% in
1999 to 92.3% in 2018. The proportion of person-time
with VL < 200 copies/ml increased from 31.3% in 1999
to 95.6% in 2018. VLs of 50- < 200 copies/ml, 200- < 500
copies/ml and 500- < 1000 copies/ml were observed in
9.1, 7.4 and 4.8% of the people in 1999, respectively, and
in 3.3, 0.8 and 0.4% of the people in 2018, respectively.
The proportion of people with viremia > 1000 copies/ml
therefore decreased from 56.4% in 1999 to 3.1% in 2018
(see Fig. 2 and Table 2 for detailed results).
People who initiated ART
A total of 22,120 people were included in the analysis
with a total follow-up time of 164,691 PY, a median ob-
servation time of 6.5 years (IQR 2.8–11.5) and a median
time under ART of 5.5 years (IQR 2.3–9.9). The total
number of real VL measurements was 490,352, the me-
dian number of VL measurements per person was 17
(IQR 8–32), and VL monitoring occurred at a median
frequency of every 91 days (IQR 70–112). With the
model, 3,974,309 virtual VL values were generated. The
real VL measurements and the virtual VL values oc-
curred on the same date in 52,205 cases.
At 88.9% (N = 19,663), the majority were enrolled in
ClinSurv HIV, 8.7% (N = 1936) were enrolled in the
HIV-1 Seroconverter cohort, and 2.4% (N = 521) were
enrolled in both cohort studies. The characteristics of
the study population who ever initiated ART are sum-
marized in Table 1.
On an individual level, a total of 94% (20,849/22,120)
achieved viral suppression after ART initiation, and 6%
(1271/22,120) never achieved viral suppression. Of all,
86% (19,076/22,120) showed viremia at any time, and
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Table 1 Characteristics of the study population (1999-2018)
Patients Study population
(all diagnosed PLHIV)
People who initiated ART
24,569 (100%) 22,120 (100%)
Observation time Total PY 171,990 164,691
Sex Male 19,794 (81%) 17,794 (80%)
Female 4775 (19%) 4326 (20%)
HIV transmission risk Men who have sex with men (MSM) 13,006 (53%) 11,676 (53%)
Heterosexual contacts 3227 (13%) 2954 (13%)
High prevalence country 3200 (13%) 2958 (13%)
People with injecting drug use 1612 (7%) 1411 (6%)
Other 212 (1%) 203 (1%)
Unknown 3312 (13%) 2918 (13%)
Region of origin Germany 16,683 (68%) 15,065 (68%)
Eastern Europe 682 (3%) 592 (3%)
Central Europe 1129 (5%) 1021 (5%)
Western Europe
(excl. Germany)
949 (4%) 834 (4%)
Africa 2998 (12%) 2749 (12%)
Asia 686 (3%) 649 (3%)
America 546 (2%) 491 (2%)
Caribbean/Ozeania 107 (0%) 96 (0%)
Unknown 789 (3%) 623 (3%)
Age at Enrolment (years) Median (IQR) 37 (30-45) 37 (31-45)
Enrollment 1999–2001 3422 (14%) 3098 (14%)
2002–2005 5454 (22%) 4834 (22%)
2006–2009 5529 (23%) 4925 (22%)
2010–2013 5343 (22%) 4819 (22%)
2014–2018 4821 (20%) 4444 (20%)
Observation time (years) Median (IQR) 5.9 (2.4-11) 6.5 (2.8-11.5)
Number of viral loads Median (IQR) 18 (7-35) 17 (8-32)
Distance between viral loads (days) Median (IQR) 91 (64–112) 91 (70–112)
Viral load
baseline (copies/ml)
Median (IQR) 49,973 (9350–198,000) 55,544 (10,899–211,000)
CD4 cell count
baseline (cells/μl)
Median (IQR) 349 (174–537) 328 (157–513)
Initiated ART N (%) 22,120 (90%)





not started ART 2449 (11%)
Age at ART start (years) Median (IQR) 39 (32-46)
Time between enrollment and ART (days) Mean (IQR) 321 (0–237)
Viral load
ART start (copies/ml)
Median (IQR) 62,000 (12,300-212,604)
CD4 cell count
ART start (cells/μl)
Median (IQR) 271 (133–429)
ART duration (years) Median (IQR) 5.5 (2.3-9.9)
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77% (17,085/22,120) showed viremia with VL > 1000
copies/ml. The total median observation time was 2010
days (IQR 850–3620). The median person-time with
viral suppression among all people was 1100 days (IQR
330–2310). The resulting individual proportion of
person-time with viral suppression to the observation
time had a median of 66% (IQR: 36–86). Excluding
gap time, the proportion of person-time with viral
suppression to the observation time had a median of
88% (IQR: 63–97). The median person-time with
viremia with VL > 1000 copies/ml was 40 days (IQR
10–110). The individual proportion of person-time
with viremia with VL ≥1000 copies/ml to the obser-
vation time had a median of 2.3% (IQR: 0.3–9). Ex-
cluding gap time, the proportion of viremia with VL
≥1000 copies/ml to the observation time had a me-
dian of 2.9% (IQR: 0.4–13).
Viral suppression and viremia from 1999 to 2018
Among PLHIV after ART initiation
Based on the longitudinal model, the proportion of
person-time with viral suppression (VL < 50 copies/ml)
of the 22,120 people who ever initiated any type of ART
increased over time from 33.6% in 1999 to 93.0% in
2018. The proportion of person-time with VL < 200 cop-
ies/ml increased from 47.0% in 1999 to 96.3% in 2018.
VLs of 50- < 200 copies/ml, 200- < 500 copies/ml and
500- < 1000 copies/ml were observed in 13.4, 10.5 and
5.2% of the people in 1999, respectively, and in 3.3, 0.8
and 0.3% of the people in 2018, respectively. The pro-
portion of people with viremia > 1000 copies/ml there-
fore decreased from 37.3% in 1999 to 2.6% in 2018 (see
Fig. 3 and Table 3a for detailed results).
Viral suppression and viremia from 1999 to 2018 using
the most recent VL in each year
Among PLHIV after ART initiation
According to a conventional definition, viral suppres-
sion, as the last step of the HIV continuum of care, is
defined as the number and percentage of people receiv-
ing medical care whose most recent HIV VL is sup-
pressed. Following this definition and considering the
last VL measurement in each year, the proportion of
people with viral suppression among the 22,120 people
who ever initiated ART and had a documented VL value
increased over time from 51.7% in 1999 to 93.3% in
2018. The proportion of people with VL < 200 copies/ml
increased from 61.1% in 1999 to 96.5% in 2018. VLs of
50- < 200 copies/ml, 200- < 500 copies/ml and 500- <
1000 copies/ml were observed in 9.4, 7.4 and 3.6% of the
people in 1999, respectively, and in 3.2, 0.9 and 0.3% of
the people in 2018, respectively. The proportion of
people with viremia > 1000 copies/ml therefore decreased
from 27.9% in 1999 to 2.3% in 2018 (see Table 3b for
detailed results).
Fig. 2 Viral load levels of all diagnosed PLHIV in the study population from 1999 to 2018
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Continuous viral suppression over one year
A total of 11,837 people with 35,995 VL measurements
were eligible for the analysis of continuous viral suppres-
sion over a one-year observation period on an individual
level. In total, at the individual level, 88% (10,474/11,
837) had no viral failure and showed continuous viral
suppression with all VLs in 2018. The median number
of VLs was 3 (IQR: 2–4), and 91% (10,792/11,837) had
more than one VL. Categorizing those with 1 VL or
more than 1 VL measurement, 81% (848/1045) and 89%
(9626/10,792) showed continuous viral suppression,
respectively. In comparison, using the last VL, 93% (11,
044/11,837) showed viral suppression, which is 5%
higher than the proportion with continuous viral
suppression on the individual level. Using all of the
available VL measurements, 93% (33,619/35,995) of the
VL showed viral suppression.
Analysis of people with gap time (VL measurements
> 180 days apart)
On an individual level of all 22,120 people who had ever
initiated ART, 8023 (36%) had no gap time, and 14,097
(64%) had any gap time. The cumulative median gap
time was 560 days (IQR: 260–1150), and the individual
proportion of gap time to the observation time had a
median of 27% (IQR: 12–47). The median number of
gaps was 2 (IQR: 1–4), and the median gap time per gap
was 223 days (IQR: 192–302).
A total of 8173 people with 15,892 VL measurements
were eligible for the analysis of the last VL before and
the first VL after gap time in the recent period from
2015 to 2018. Of all VL measurements, 90% (14,274/15,
892) and 90% (14,293/15,892) showed viral suppression
at last VL before and first VL after gap time, respect-
ively. Furthermore, 4% (599/15,892) and 3% (531/15,892)
had VL > 50- < 200 copies/ml, 1% (221/15,892) and 2%
(227/15,892) had VL 200- < 1000 copies/ml, and 5%
(798/15,892) and 5% (841/15,892) had VL ≥1000 copies/
ml at the last VL before and the first VL after gap-time,
respectively. Overall, among those with viremia, the me-
dian VL was 910 copies/ml (IQR: 104–25,700) and 1368
copies/ml (IQR: 118–31,853) for the last VL before and
the first VL after gap-time, respectively.
On an individual level, of all last VLs before and first
VLs after gap time, 86% were congruent with each other,
with 84% showing viral suppression, 0.8% having VL 50-
Table 2 Development of person-time with viral suppression and viremia among all diagnosed PLHIV in the cohorts, including ART-
naïve and treated person-time between 1999 and 2018 based on our longitudinal model
All diagnosed people living with HIV
Year Viral suppression
(< 50)
50 - < 200 200 - < 500 500 - < 1000 1000 - < 10,000 10,000 - < 100,000 100,000 - < 1.000000 > 1000,000
1999 22.2 9.1 7.4 4.8 18.2 24.5 12.8 0.8
2000 39.0 8.4 5.5 3.8 13.8 20.7 8.4 0.3
2001 45.0 7.2 4.3 3.2 13.8 18.2 7.9 0.3
2002 46.7 6.7 4.1 2.9 12.6 19.2 7.6 0.2
2003 50.8 6.0 3.2 2.2 11.3 17.9 8.2 0.4
2004 50.6 6.4 3.1 2.2 10.7 18.7 8.1 0.3
2005 52.8 6.3 3.0 2.3 10.6 17.9 6.9 0.3
2006 55.5 6.4 3.0 2.1 10.7 16.7 5.3 0.3
2007 58.1 6.7 2.7 2.0 9.7 15.9 4.5 0.3
2008 62.0 6.5 2.6 1.8 9.0 13.3 4.6 0.3
2009 65.3 6.2 2.2 1.6 7.7 12.8 4.1 0.3
2010 68.7 6.5 2.2 1.5 6.5 11.2 3.2 0.2
2011 73.2 6.6 2.0 1.3 5.4 8.7 2.6 0.2
2012 75.6 6.2 2.0 1.2 5.0 7.5 2.3 0.2
2013 78.6 5.8 1.8 1.1 4.2 6.3 2.1 0.2
2014 83.6 4.8 1.3 0.9 3.3 4.9 1.1 0.1
2015 a 86.7 a 3.8 a 1.1 0.8 2.8 3.8 0.9 0.1
2016 88.3 4.4 1.0 0.7 2.3 2.4 0.9 0.1
2017 b 91.3 b 3.7 0.8 0.5 1.5 1.5 0.6 0.1
2018 92.3 3.3 0.8 0.4 1.2 1.2 0.6 0.1
a The UNAIDS target of viral suppression with VL < 200 copies/ml has been met for all diagnosed PLHIV in the study population in Germany since 2015
b The UNAIDS target of viral suppression with VL < 50 copies/ml has been met for all diagnosed PLHIV in the study population in Germany since 2017
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< 1000 copies/ml and 1.1% having VL ≥1000 copies/ml.
A total of 14% were not congruent with another, with
7% having a VL increase and 7% with a VL decrease
(Table 4).
To approximate the impact of gap time on the overall
viral suppression in people who initiated ART, we calcu-
lated the resulting proportion of viral suppression after
considering for viremic gap time. Figure 4 shows the
proportion of viral suppression and viral load levels in
people with gap time at their first VL measurement after
gap time between 1999 and 2018. Additionally, it shows
the proportion of gap time among all people who initi-
ated ART, the proportion of viral suppression among all
people who initiated ART and the resulting proportion
of viral suppression among all people who initiated ART
after considering for viremic gap time. The proportion
of gap time was lowest in 1999 and 2018 at 18% and
highest in 2003, 2005 and 2016 at 28%, and the mean
and median gap time were both 24%. The proportion of
viremic gap time ranged from approximately 12% be-
tween 1999 and 2005, then decreased constantly to 2%
in 2018. The resulting proportion of viral suppression
among all people who initiated ART after considering
for viremic gap time increased from 21% in 1999 to 90%
in 2018.
Analysis of antiretroviral treatment regimens over time
The exact composition of ART regimens in the cohort
studies is shown in Fig. 5 and Table S1. Overall, NRTI/
NNRTI regimens with 35% were most frequently used,
followed by 32% NRTI/PI regimes and 16% NRTI/INSTI
regimens. The remaining 17% were divided between less
common or older regimens, and 5% had treatment inter-
ruptions. The composition of ART regimens in the co-
hort studies changed significantly over time. Between
1999 and 2014, NRTI/PI regimens were at approxi-
mately 35%, and this proportion decreased thereafter to
18% in 2018. NRTI/NNRTI regimens ranged from ap-
proximately 35 to 40% between 1999 and 2014 and then
decreased to 25% in 2018. NRTI/INSTI regimens con-
tinuously increased after their market entry in 2006,
reaching 3% in 2010 and 11% in 2013 and further in-
creasing to 47% in 2018. In 1999, a proportion of 10%
was NRTI-only regimens, and this proportion decreased
from 2004 to 0.4% in 2018. NRTI sparing regimens con-
tinuously increased from 0.3% in 1999 to 4% in 2018.
The proportion of not fully active ART was 6% in 1999
but continuously decreased over time to only 0.5% in
2018. Interruptions were highest in 2001 to 2006 at up
to 13% and then decreased continuously from 2007 on-
ward to 1% in 2018 (see Fig. 5 and Table S1).
Discussion
Summary
We developed a model to reconstruct the individual viral
load course of people to estimate the durations and
proportions of viral suppression and viremia using longi-
tudinal clinical cohort data, including all available VL
Fig. 3 Viral load levels of people who ever initiated any ART in the study population from 1999 to 2018
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measurements, additionally taking into account ART
status and VL dynamics. The method provides a nation-
wide estimate and a useful method for calculating the
number and proportion of PLHIV and of person-time
with viral suppression for the HIV care continuum to
evaluate the UNAIDS target of viral suppression for
Germany. This model additionally allows for the deter-
mination and further analyses of people with longer pe-
riods without observation or missing VL control, defined
as gap time. We determined the proportion of person-
time and PLHIV with viral suppression and gap time be-
tween 1999 and 2018 using longitudinal national cohort
data. We observed a continuous and remarkable increase
in the proportion of person-time and of PLHIV being
virally suppressed in both the whole study population
and in PLHIV after ART initiation. The 90% UNAIDS
target of viral suppression has been met in the whole
study population of all diagnosed PLHIV since 2017 due
to earlier and widespread use of ART and in PLHIV
after ART initiation since 2015, respectively. Using the
international comparable threshold of 200 copies/ml, the
target was reached since 2015 and 2011, respectively. In
2018, 93% of PLHIV after ART initiation were virally
suppressed with VL < 50 copies/ml, and 96% had VL <
200 copies/ml. Furthermore, we compared the results of
the conventional method with those of our longitudinal
method, showing potential misclassification of viral sup-
pression when using only the last VL in a year. We ob-
served a constant high proportion of gap time in these
real-life cohort studies. We further analyzed people with
Table 4 Congruence of last VL before and first VL after gap time, viral suppression (VS) and median VL for each group and
overall between 2015-2018
Congruence N (%) Last VL before gap time First VL after gap time
N no VS (%) no VS Median (IQR) N no VS (%) no VS Median (IQR)
Congruent VS 13,407 84.4 – – – – – –
Congruent 50- < 1000 134 0.8 134 100 88 (66–160) 134 100 93 (66–149)
Congruent > =1000 170 1.1 170 100 33,180 (7200-83,550) 170 100 33,180 (8900–73,827)
VL decrease
last VL > first VL
1051 6.6 1051 100 1162 (101–31,300) 165 16 278 (101–1820)
VL increase
last VL < first VL
1130 7.1 263 23 326 (114–2555) 1130 100 1667 (135–33,824)
Total 15,892 100.0 1618 10 910 (104–25,700) 1599 10 1368 (118–31,853)
Fig. 4 Proportion of viral suppression and viral load levels in people with gap time at their first VL measurement after gap time between 1999
and 2018. Additionally, the proportion of gap time among all people who initiated ART (grey line), the proportion of viral suppression among all
people who initiated ART (blue line) and the resulting proportion of viral suppression among all people who initiated ART after considering for
viremic gap time (black line) is shown
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gap time, aiming to approximate their viral load status,
and we showed that, in recent years, only a slightly lower
proportion of viral suppression was associated with gap
time.
Longitudinal model and comparison with the
conventional method
Viral suppression is conventionally determined based on
the most recent HIV viral load below a certain thresh-
old, often < 200 copies/ml for comparability across
studies and different settings and because this threshold
was shown to be sufficient to avoid HIV transmission
[17, 18, 30]. However, such a cross-sectional approach
does not address the timeliness of either reaching or the
time spent at each level [6] and person-time with viral
suppression and viremia. Using a single VL measure-
ment can lead to an overestimation of durable viral sup-
pression [6, 22]. In our approach, instead of considering
only the last VL measurement in a respective year, we
examined the total observation time with all available
VL measurements and additionally created virtual VL
values taking into account ART status and VL dynamics
to reconstruct persons’ individual viral load courses. We
believe that this approach provides a more accurate pic-
ture of the VL status of the study population and might
be especially useful when the study population and sam-
ple size are smaller and therefore less robust. When
examining a large number of people cross-sectionally, it
is likely that, at each point in time, a certain more or less
stable proportion of people shows viral suppression. In
this study, the proportion of people with viral suppres-
sion in recent years using the conventional approach
with the last VL per year was ~ 2% higher than in our
longitudinal model. Although this difference is small, it
might be due to the large numbers of people and mea-
surements included, which could reflect an overesti-
mation of durable viral suppression and could be
different in smaller studies or other settings. From 1999
to 2001, when the study size was smaller, the difference
was ~ 11%. Furthermore, the comparison of the conven-
tional cross-sectional approach with the analysis of
continuous viral suppression in one year on an individ-
ual level showed a notable difference of 5%. Recent stud-
ies have also demonstrated that simple, cross-sectional
measures of viral suppression are prone to misclassifica-
tion [31]. Viral suppression is not constant once achieved,
and people often transition between suppressed and un-
suppressed states, even over periods as short as one year
[21]. Therefore, in agreement with the results of other
studies, we believe that the dynamics of VL progression
are easily overlooked with a cross-sectional assessment of
the last VL measure, and longitudinal measures of VL dy-
namics provide more granular data with implications for
HIV treatment and prevention [21, 22, 31]. Additionally,
*Salvage regimen (3 classes and attachment inhibitors or fusion inhibitors or 4 classes)
Fig. 5 Composition of ART regimens by drug classes in the cohort studies from 1999 to 2018
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with our model, it is possible to assign, quantify and
further investigate longer periods without observation or
VL control. For the reasons described, we believe that our
method is superior when examining trends over time in
longitudinal long-term cohorts with potential observation
gaps and viral load changes. In addition, it should be em-
phasized that this advantage can be achieved on the basis
of already established standards of therapy monitoring
and thus with reasonable effort.
Gap time and retention in care
In our study, we defined longer periods without viral
load control of more than 180 days between VL mea-
surements as gap time. A notable proportion of 24% gap
time was observed in these real-life cohort studies. The
question of whether these people are considered suc-
cessfully treated or whether having viremia is a factor of
uncertainty in our analysis. However, following an ap-
proach using the last VL measure for viral suppression
would not consider this proportion at all. Aiming to
approximate the status of the people during gap time,
we analyzed the last and first VL measurements before
and after gap time. On an individual level, 84% of the
people came back into observation with the same VL
with which they left showing viral suppression. The
overall proportion of virally suppressed before and after
gap time in recent years was 90%, which is only slightly
(3%) less than using our longitudinal model excluding
gap time. In our opinion, it is therefore very unlikely to
assume that the people had high VL only during their
gap time, and we believe that the VL measurements be-
fore and after gap time are good proxies. Furthermore,
the median VL of the 10% with viremia before and after
gap time decreased remarkably over time. Finally, we
calculated the resulting proportion of viral suppression
after considering for viremic gap time and showed that
this would decrease the overall viral suppression by only
2% among all people who initiated ART in 2018. One
reason for viral suppression or low viremia during gap
time can be that people were receiving care in non-
cohort centers rather than being lost to care entirely. It
is important to note again that these nationwide studies
are real-life observational cohorts that reflect clinical
practice. People might switch doctors or leave the coun-
try or region for a certain time and then return, or it is
also possible that the gaps in observation and longer
periods without VL controls are in fact gaps in docu-
mentation. These might be reasons for the constant high
proportion of gap time in the studies. However, VL can
be very dynamic, and after ART interruption, even in
selected cases with long-term viral suppression, in the
absence of plasma residual viremia and low HIV-DNA
or people treated in Fiebig I acute infection, viral re-
bound occurred rapidly at a median time of 21 or 26
days, respectively [32, 33]. Longer periods without VL
control are therefore problematic. Potentially, even the
quarterly reimbursed VL testing in Germany would not
be sufficient to detect every single VL even if counting
them as blips, and from a researcher’s perspective, we
might wish to have information about the VL status of
each person for every day. However, evidence has shown
that quarterly VL testing is sufficient to determine treat-
ment success, which is reflected in guidelines [26] and
reimbursement regulations. Nonetheless, at least all of
the available VLs should be used to determine the pro-
portion of virally suppressed people in one year, instead
of reducing the available data to only one VL per year.
In our model, we use all available VLs, additionally tak-
ing into account the ART status and VL dynamics of the
people to generate virtual VL values along a line, enab-
ling us to assign a VL status at any point in observa-
tional time. We confirmed that VL testing occurred
every 91 days in our cohorts, showing again that ART in
Germany is performed by highly specialized practitioners
in accordance with the guidelines [26]. Conversely, we
also observed a constant high proportion of 24% gap
time in the cohort studies, with a slightly higher likeli-
hood of showing viremia. Retention in care is crucial for
successful treatment, and we recommend maintaining
engagement and retention in care and adherence to
ART, accompanied, guided and monitored by regular
VL testing. We also recommend further analysis among
people with gap time, which we have planned. However,
the achieved improvements in HIV care and treatment
by highly specialized doctors are not doubted and can be
seen in the composition of ART regimens over time and
not least in the remarkable increase in viral suppression
over time.
Trends of viral suppression between 1999 and 2018
Between 1999 and 2018, after ART initiation, the pro-
portions of person-time and of PLHIV with viral sup-
pression increased from 34 to 93%. With the threshold
of VL < 200 copies/ml between 1999 and 2018, the pro-
portion of person-time and PLHIV after ART initiation
increased from 47 to 96%. A remarkable increase in viral
suppression has also been observed in many other stud-
ies and countries [4, 5, 34–38]. These findings are likely
explained by improvements in clinical care, treatment
options and ART adherence [13, 35, 38]. Although not
all regimens or drugs are still being equally used, treat-
ment options have remarkably increased since the early
era after the introduction of highly active, combined
ART. Not fully active ART was at 6% in 1999 but soon
continuously decreased to only 0.5% in 2018. The
experience of practitioners and people in using ART and
the importance of adherence have improved tremen-
dously. Resistance test-guided therapy is now the
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standard [26]. Much has been learned with regard to
treatment interruptions, and at least since the results of
the SMART study in 2006, interruptions are no longer
recommended [39]. This learning can very well be seen
in the proportion of interruptions in the RKI cohorts.
Treatment interruptions in our study were highest at
13% in 2004 and 2005 and subsequently decreased to
less than 1% in 2018. During 2015–2018 in our study
population, ART interruptions still occurred in 1–2% of
the people. Since ART is lifelong, we included all people
who ever initiated ART even if treatment was inter-
rupted, indicating that the proportion of viral suppres-
sion would be even higher if we restricted them to those
under continuous ART. We also assessed the VL in the
whole study population regardless of ART initiation, in-
cluding ART-naïve people and person-time. An impres-
sive increase was observed for all diagnosed PLHIV,
which, as the results of the ClinSurv HIV and HIV-1
Seroconverter cohort showed [40], was connected with
the widespread and earlier use of ART as recommended
in the guidelines [26]. This achievement is a great one in
terms of treatment as prevention (TasP), showing that,
since early ART is common, the population of diagnosed
PLHIV is not substantially contributing to HIV trans-
mission in Germany. This fact shows that diagnosis is
key to prevention. With regard to the whole HIV care
continuum, we know that the potential for improvement
is mostly seen at this first stage of the HIV care con-
tinuum -- the only stage for which Germany has not yet
met the UNAIDS target of 90% [8]. Therefore, tailored
HIV testing campaigns and enhanced access to HIV test-
ing, including self-testing, should be further strength-
ened. For PLHIV after ART initiation, we recommend
avoiding treatment interruptions and emphasizing ad-
herence to ART.
Evaluation of the UNAIDS 90 target of viral suppression
The UNAIDS target of 90% viral suppression has been
met among PLHIV who ever initiated ART since 2015
in these nationwide German cohort studies of PLHIV.
The international comparable threshold of VL < 200
copies/ml has been met among PLHIV who ever initi-
ated ART since 2011. In 2018, 93% of PLHIV after ART
initiation were virally suppressed with VL < 50 copies/
ml, and 96% had VL < 200 copies/ml. Therefore, when
using the threshold of VL < 200 copies/ml, Germany
reached the UNAIDS 95 target of viral suppression since
2017. On a population basis in light of the HIV trans-
mission risk, studies have suggested that a VL up to 400
copies/ml might still be uncritical [41]. A notable propor-
tion of our study population with viremia showed low-
level viremia < 1000 copies/ml with a likely low risk of
transmitting HIV [30]. However, individual health risks
[42], the development of HIV drug resistance [43–45] and
increased risk of viral rebound [46–48] among people with
low-level viremia are problematic, and viral suppression
remains the goal [49]. Therefore, further analysis of people
with viral failure is essential.
Limitations
Assessing stages of the HIV continuum of care using
cohorts can introduce bias since they might not be
representative of all diagnosed PLHIV in a country.
To estimate representativeness, we compared the
demographic characteristics of our study population
with all PLHIV in Germany and found them to be
similar. The study population represents more than
20% of all PLHIV in Germany. ClinSurv HIV is the
largest nationwide long-term cohort of HIV-positive
people and the least biased source available. In a
study by Gourlay et al., the authors also used
country-specific cohort data to derive stages of the
HIV care continuum in European Union countries
[6]. Germany delivered data from ClinSurv HIV for
this study and was assumed to be fairly representative
of HIV people in care [6, 50, 51]. People outside of
medical care, e.g., without health insurance, are not
represented in ClinSurv. The HIV-1 Seroconverter co-
hort is assumed to be representative of men who have
sex with men (MSM) in Germany [52] and therefore
covers one specific group within the population of
PLHIV. However, MSM is the largest group and is
mainly affected by HIV; furthermore, ClinSurv HIV
accounts for more than 90% of the study population
in our analytic sample. In this respect, we believe that
the representativeness of ClinSurv HIV applies, and
following the results of Gourlay et al., our sample is
fairly representative of HIV people in care in
Germany. However, we cannot exclude that these
studies are not representative.
As discussed, gap time is a factor of uncertainty, and al-
though we believe that our sensitivity analysis of the last
and first VL before and after gap time is a reasonable ap-
proximation, viral suppression was slightly lower, indicat-
ing that further analyses of people with gap time would be
useful. Furthermore, in real-life studies, misclassification,
loss to follow-up, lab-related issues and gaps in documen-
tation can occur and influence gap time.
Conclusions
This report describes a model to estimating the number
and proportion of PLHIV and person-time with viral
suppression. The study provides a possible approach for
estimating the number of people receiving continuously
specialized HIV medical care in Germany and those with
gaps in observation or VL control. With this study, we
provide a nationwide estimate and a useful tool for
calculating the number and proportion of PLHIV and of
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person-time with viral suppression and with gap time as
well as trends of viral suppression and gap time between
1999 and 2018 in Germany. We observed an increase in
the proportion of person-time and of diagnosed PLHIV
with viral suppression. The UNAIDS 90 target of viral
suppression has been met in these nationwide German
cohort studies since 2015 and, when using the inter-
national comparable threshold of < 200 copies/ml, since
2011. In 2018, 93% of PLHIV after ART initiation were
virally suppressed with VL < 50 copies/ml, and 96% had
VL < 200 copies/ml. Germany reached the UNAIDS 95
target of viral suppression since 2017 when using the
threshold of VL < 200 copies/ml. Our results suggest
that the population of diagnosed PLHIV is not substan-
tially contributing to HIV transmission in Germany.
Continuous efforts toward tailored HIV testing cam-
paigns and enhanced access to HIV testing, including
self-testing, are recommended.
We also recommend regular VL testing and engage-
ment and retention in care as well as adherence to con-
tinuous ART. Further analysis of people with viral
failure is essential to understand and determine risk
factors for viral failure in times of highly effective and
mostly successful ART.
This approach and model to reconstruct persons’ indi-
vidual viral load course can be useful for estimating the
number and proportion of PLHIV with viral suppression
in other countries, provided that the required resources
are available. The described methodology could be used
and adapted for different investigations or parameters in
the future.
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